Abstract:Compelling evidence has described that the incidence of hypertension and left ventricular hypertrophy (LVH) in postmenopausal women is significantly increased worldwide. Our team's previous research identified that androgen was an underlying factor contributing to increased blood pressure and LVH in postmenopausal women. However, little is known about how androgens affect LVH in postmenopausal hypertensive women. The purpose of this study was to evaluate the role of mammalian rapamycin receptor (mTOR) signaling pathway in myocardial hypertrophy in androgen-induced postmenopausal hypertension and whether mTOR inhibitors can protect the myocardium from androgen-induced interference to prevent and treat cardiac hypertrophy. For that, ovariectomized (OVX) spontaneously hypertensive rats (SHR) aged 12 weeks were used to study the effects of testosterone (T 2.85 mg/kg/weekly i.m.) on blood pressure and myocardial tissue. On the basis of antihypertensive therapy (chlorthalidone 8 mg/kg/day ig), the improvement of blood pressure and myocardial hypertrophy in rats treated with different dose gradients of rapamycin (0.8 mg/kg/day vs 1.5 mg/kg/day vs 2 mg/kg/day i.p.) in OVX + estrogen (E 9.6 mg/kg/day, ig) + testosterone group was further evaluated. After testosterone intervention, the OVX female rats exhibited significant increments in the heart weight/tibial length (TL), area of cardiomyocytes and the mRNA expressions of ANP, β-myosin heavy chain and matrix metalloproteinase 9 accompanied by a significant reduction in the uterine weight/TL and tissue inhibitor of metalloproteinase 1. mTOR, ribosomal protein S6 kinase (S6K1), 4E-binding protein 1 (4EBP1) and eukaryotic translation initiation factor 4E in myocardial tissue of OVX + estrogen + testosterone group were expressed at higher levels than those of the other four groups. On the other hand, rapamycin abolished the effects of testosterone-induced cardiac hypertrophy, decreased the systolic and diastolic blood pressure of SHR, and inhibited the activation of mTOR/S6K1/4EBP1 signaling pathway in a concentration-dependent manner. Collectively, these data suggest that the mTOR/S6K1/4EBP1 pathway is an important therapeutic target for the prevention of LVH in postmenopausal hypertensive female rats with high testosterone levels. Our findings also support the standpoint that the mTOR inhibitor, rapamycin, can eliminate testosterone-induced cardiomyocyte hypertrophy.

The mammalian target of rapamycin modulates the immunoproteasome system in the heart

Mammalian target of rapamycin is essential for cardiomyocyte survival and heart development in mice.

Mammalian target of rapamycin inhibition attenuates myocardial ischaemia-reperfusion injury in hypertrophic heart

Rapamycin Inhibits Cardiac Hypertrophy by Promoting Autophagy via the MEK/ERK/Beclin-1 Pathway.

Inhibition of Mammalian Target of Rapamycin with Rapamycin Reverses Hypertrophic Cardiomyopathy in Mice with Cardiomyocyte-Specific Knockout of PTEN.

Rapamycin Attenuated Cardiac Hypertrophy Induced by Isoproterenol and Maintained Energy Homeostasis Via Inhibiting NF-κB Activation

Inhibition of mTORC1 renders cardiac protection against lipopolysaccharide.

Modulating autophagy improves cardiac function in a rat model of early-stage dilated cardiomyopathy.

Curcumin Alleviates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis Through Inhibition of Autophagy and Activation of Mtor.

Hypertrophied Myocardium is Vulnerable to Ischemia/reperfusion Injury and Refractory to Rapamycin-Induced Protection Due to Increased Oxidative/nitrative Stress.

Genetic and Pharmacological Inhibition of Rheb1-Mtorc1 Signaling Exerts Cardioprotection Against Adverse Cardiac Remodeling in Mice

MTOR INHIBITOR IMPROVES TESTOSTERONE-INDUCED MYOCARDIAL HYPERTROPHY IN HYPERTENSIVE RATS.

Mechanistic target of rapamycin in regulating macrophage function in inflammatory cardiovascular diseases

Rapamycin Reverses Pulmonary Artery Smooth Muscle Cell Proliferation in Pulmonary Hypertension.

mTOR inactivation in myocardium from infant mice rapidly leads to dilated cardiomyopathy due to translation defects and p53/JNK-mediated apoptosis

Identification of Reduced mTOR T1262 Phosphorylation as a Novel Mechanism and Therapeutic Target of Apoptosis in Senescent Cardiomyocytes: Aging and Cardiomyocyte Apoptosis

Mammalian Target of Rapamycin Overexpression Antagonizes Chronic Hypoxia-Triggered Pulmonary Arterial Hypertension Via the Autophagic Pathway.

Research Progress of mTOR Signaling Pathway Effect in Cardiac Development and Reconstruction

The mTOR signaling pathway in cardiac aging

Rapamycin Improves Cardiac Function of Myocardial Infarction Mice by Reducing the Expression of Inflammatory Cytokines

Inhibition of Mtor Attenuates Store-Operated Ca2+ Entry in Cells from Endarterectomized Tissues of Patients with Chronic Thromboembolic Pulmonary Hypertension